AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03486561
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
Trial: NCT00524927
Drug: Methoxyflurane
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00621777
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks.
Trial: NCT01008319
Drug: clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Trial: NCT01008319
Drug: clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Trial: NCT00194129
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
Trial: NCT00194129
Drug: Divalproex
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
Trial: NCT00112827
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02492802
Drug: posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: collection plasma samples for measuring posaconazole drug concentration
Trial: NCT00112827
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT03234036
Drug: Ritonavir 100 mg tablets
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It is a white film-coated ovaloid tablets.
Trial: NCT00353522
Drug: dalcetrapib
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900mg po daily for 24 weeks
Trial: NCT01126099
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg capsules twice daily for 12 weeks
Trial: NCT03475277
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration
Trial: NCT02984293
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg once daily for 28 days.
Trial: NCT01879722
Drug: TAK-063
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 tablets
Trial: NCT00434213
Drug: Daytrana
RxNorm normalized name: Daytrana
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate Transdermal System (MTS)
Trial: NCT02468180
Drug: N-butyl-2-cyanoacrylate
RxNorm normalized name: N-butyl-2-cyanoacrylate
DrugBank: Enbucrilate (DB12358)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01189175
Drug: BI 113823 + Ketokonazole
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days ketokonazole with single oral dose of BI 113823 on day 3
Trial: NCT01189175
Drug: BI 113823
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT03535961
Drug: apatinib+oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
Trial: NCT02580305
Drug: SUVN-502
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, tablets, orally
Trial: NCT02580305
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl (10 mg, once a day)
Trial: NCT02580305
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Trial: NCT02828540
Drug: HT047 Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
Trial: NCT04278222
Drug: Anlotinib Plus Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
Trial: NCT04363060
Drug: amoxicillin/clavulanate
RxNorm normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
Trial: NCT01913301
Drug: Alagebrium
RxNorm normalized name: Alagebrium
DrugBank: Alagebrium (DB12497)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01653847
Drug: Group 2: Tacrolimus with Everolimus.
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is \> 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
Trial: NCT01198925
Drug: piperacillin continuous infusion
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: piperacillin continuous infusion
Trial: NCT01198925
Drug: piperacillin extended infusion
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: piperacillin extended infusion
Trial: NCT00003601
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00388362
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
Trial: NCT00388362
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
Trial: NCT02453464
Drug: Sevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
Trial: NCT02453464
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
Trial: NCT02453464
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
Trial: NCT04908436
Drug: Finerenone (BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg BAY94-8862 immediate release (IR) tablet, administered orally
Trial: NCT00972946
Drug: Administration of Endorem
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose, intravenous
Trial: NCT01812434
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg three time daily for 28 days
Trial: NCT01123876
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
Trial: NCT00774930
Drug: Lanreotide
RxNorm normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: deep s.c. injection, 120 mg, every 4 weeks (±3 days).
Trial: NCT01833845
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
Trial: NCT01833845
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
Trial: NCT01236534
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mcg twice daily for 21 days.
Trial: NCT00491725
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00491725
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03734159
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Trial: NCT03734159
Drug: sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Trial: NCT00580242
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Trial: NCT00580242
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Trial: NCT00580242
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Trial: NCT01672450
Drug: Intratumoral Ipilimumab and Interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
Trial: NCT00580242
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
Trial: NCT01079663
Drug: Chlorhexidine 2.5 mg
RxNorm normalized name: chlorhexidine 2.5 MG
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01844687
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Trial: NCT02334163
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg nitazoxanide tablets twice daily
Trial: NCT02334163
Drug: Oral lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral lactulose (65%)
Trial: NCT02334163
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg metronidazole tablets every 8 hours
Trial: NCT02334163
Drug: Rifaximine
RxNorm normalized name: Rifaximine
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 200 mg rifaximine tablets every 8 hours
Trial: NCT02144766
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caudal block with 1 ml/kg of ropivacaine 0.2%
Trial: NCT02144766
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caudal block with 1 ml/kg of saline
Trial: NCT01607411
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride Toothpaste
Trial: NCT01283204
Drug: SP
RxNorm normalized name: Asp
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest.
Trial: NCT03477162
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin will be given to patients prior to surgery.
Trial: NCT01556191
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg per day (oral)
Trial: NCT01556191
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
Trial: NCT01556191
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg per day (oral)
Trial: NCT01856868
Drug: (-)-epicatechin
RxNorm normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
Trial: NCT00371683
Drug: Enoxaparin + Placebo
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
Trial: NCT00371683
Drug: Apixaban + Placebo
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
Trial: NCT04717245
Drug: Promestriene Vaginal
RxNorm normalized name: promestriene Vaginal Cream
DrugBank: Promestriene (DB12487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
Trial: NCT01486940
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
Trial: NCT01486940
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
Trial: NCT00092196
Drug: MK0869, aprepitant / Duration of Treatment: 3 days
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01507181
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose IV ketamine, .5mg/kg infused over 40 minutes
Trial: NCT01507181
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose IV midazolam, .45mg/kg infused over 40 minutes
Trial: NCT02546648
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02546648
Drug: Tranexamic Acid Placebo
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02785393
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of a sugar pill
Trial: NCT02785393
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The administration of the Doxazosin medication
Trial: NCT01725685
Drug: FF 400 mcg
RxNorm normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
Trial: NCT01725685
Drug: UMEC 500 mcg
RxNorm normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
Trial: NCT01034163
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02355678
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV 0.5 mg/kg
Trial: NCT02355678
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If Visual Analogue Scale was greater than 5
Trial: NCT02355678
Drug: Propacetamol hydrochloride
RxNorm normalized name: Propacetamol hydrochloride
DrugBank: Propacetamol (DB09288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If Visual Analogue Scale was between 4 and 5
Trial: NCT00526838
Drug: XL228
RxNorm normalized name: XL228
DrugBank: XL228 (DB05184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour IV infusion
Trial: NCT02581631
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02148640
Drug: Innovator infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02148640
Drug: Biosimilar infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes